NRX Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by NRX Pharmaceuticals, Inc. on February 2, 2023. The report concerns a special meeting of stockholders convened on the same date. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance.
Material Changes and Events
- Special Meeting Adjournment: The special meeting held on February 2, 2023, was adjourned because a quorum was not achieved.
- Shareholder Count: As of the record date (January 9, 2023), there were 67,690,914 shares of common stock outstanding.
- Reconvening Date: The meeting is scheduled to reconvene on February 17, 2023, at 11:00 a.m. local time in a virtual format.
- Proposal Status: No changes have been made to the proposal set forth in the definitive proxy statement filed on January 10, 2023.
Outlook, Risks, and Management Commentary
Management is continuing to solicit votes from stockholders during the adjournment period. The Company encourages all stockholders who have not yet voted to do so promptly. The record date for determining voting eligibility remains January 9, 2023. Stockholders who have already voted do not need to take further action unless they wish to change their vote.
Key Facts for Investor Verification
- Verify the specific proposal details in the definitive proxy statement filed on January 10, 2023.
- Confirm the virtual meeting link and access procedures for the reconvened meeting on February 17, 2023.
- Monitor subsequent filings to determine if a quorum is achieved and if the proposal is approved at the reconvened meeting.